Lung cancer is one of the most common cancer forms with a high mortality rate. Early diagnose and good prognosis contributes to improved survival rates. Control after surgery and follow up after cancer treatment are also important factors in the management of patients. MonoTotal® is therefore an important complement to other clinical methods.

During 2015 the patent  ”Method for detection of cytokeratin 8, 18 and/or 19 and/or soluble fragments thereof” was approved in Sweden. The patent has now been approved in China and is valid until 2034. 

"The patent means that the usefulness of this type of analysis can get the attention it deserves. Using in vitro diagnostics in combination with other analytical methods is especially pleasing to patients and also of health-economic value, "says Ylva D'Amico, Research and Development Manager at IDL Biotech AB,